Guger, Michael
Raschbacher, Stefan
Kellermair, Lukas
Vosko, Milan R.
Eggers, Christian
Forstner, Thomas
Leitner, Karin
Fuchs, Alexandra
Fellner, Franz
Ransmayr, Gerhard http://orcid.org/0000-0001-9982-1420
Funding for this research was provided by:
Oesterreichische Nationalbank (13240)
Kepler Universitätsklinikum Linz
Article History
Received: 2 May 2021
Accepted: 1 July 2021
First Online: 19 July 2021
Declarations
:
: Michael Guger received support and honoraria for research, consultation, lectures and education from Almirall, Bayer, Biogen, Celgene, Genzyme, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi Aventis, Shire and TEVA ratiopharm. Stefan Raschbacher declares no conflict of interest. Lukas Kellermair received support and honoraria for research, consultation, lectures and education from Abbvie and Pfizer. Milan Vosko received research and grant support from Österr. Forschungsförderungsgesellschaft, Fresenius, European Community—Marie-Curie Individual Fellowship Program, COST—Program 18118; and honoraria for research, consultation, lectures from Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, Ever Neuro Pharma, Novartis, Pfizer. Christian Eggers declares to have no conflict of interest. Thomas Forstner declares no conflict of interest. Karin Leitner declares no conflict of interest. Alexandra Fuchs declares no conflict of interest. Franz Fellner declares no conflict of interest. Gerhard Ransmayr received support and honoraria for research, consultation, lectures and education from Abbvie, Alpine Market Research, Österr. Forschungsförderungsgesellschaft, Grünenthal, MedAhead, Novartis, Ratiopharm, Roche, Sanofi Aventis, Stada and UCB.
: The study was conducted according to the Declaration of Helsinki and approved by the local ethical review board (Ethikkommission des Landes Oberösterreich; FTLA Study, Protocol No. 254).
: Written informed consent was obtained from the patients and their caring family members.
: Not applicable.